INTRODUCTION
Despite the existence of effective treatment, tuberculosis (TB) remains an important cause of morbidity and mortality, with an estimated 8.8 million incident cases and 1.1 million deaths globally in 2010 (1) . As in many other countries, the national health system in Turkey is responsible for planning, implementing, and monitoring TB control efforts, which are based on the World Health Organization (WHO) guidelines (2) (3) (4) (5) . TB treatment in Turkey incurs no direct costs to patients, and it is provided by dedicated TB dispensaries; treatment outcomes are monitored through case registries, facilitating the comprehensive assessment of TB epidemiology and treatment results. A total of 17,402 TB patients were registered at TB dispensaries in Turkey in 2009 for a national case notification rate of 24.0/100,000 patientyears. Istanbul, Turkey's largest city, has the highest TB incidence (44.1/100,000 patient-years) (2) .
The global targets for TB control established by the World Health Assembly in 1991 and revised in 2005 include detection of at least 70z and cure of at least 85z of new sputum smear-positive TB cases (6) . Since its introduction in the mid-1990s, the Directly Observed Treatment, Short-Course (DOTS) program has evolved to become the cornerstone of Turkey's``Stop TB Strategy'' to reach the Millennium Development Goals for TB (7) . Turkey launched these efforts in 2006 along with the Global Plan to Stop TB 2006-2015. The treatment success rate achieved in DOTS cohorts worldwide has now exceeded the global target of 85z for 2 successive years (1) . Turkey achieved a treatment success rate of 85z in 2004; further, it is continuing to improve treatment outcomes. In 2008, treatment success was achieved in 92z of smear-positive new cases (2) .
Clinical characteristics strongly influence treatment outcomes. Older age, male sex, infection with multidrug-resistant (MDR) strains, diabetes mellitus, low socioeconomic status, limited access to transportation, distance from home to treatment center, poor treatment compliance, limited interest in information about the disease and its treatment, and limited social support are associated with an increased risk of adverse treatment outcomes (8) (9) (10) (11) (12) (13) . The aim of our study was to describe the clinical and demographic characteristics of patients with pulmonary TB followed in the national TB register in Istanbul, Turkey, to examine treatment outcomes, and to identify the factors associated with adverse TB treatment outcomes.
MATERIALS AND METHODS
Setting and study population: We conducted a retrospective cohort study of adult pulmonary TB patients diagnosed between January 1, 2006 and December 31, 2009 at TB dispensaries in Istanbul with a 1-year follow-up to determine treatment outcomes. Study subjects were older than 18 years with smear-or culturepositive Mycobacterium tuberculosis pulmonary TB reported to the Turkish National Tuberculosis Registry. Beginning with 24,841 TB cases in the registry, we excluded patients younger than 18 years (n ＝ 2,624, 10.6z), patients with extrapulmonary TB only (n ＝ 5,584, 22.5z), patients transferred out to other treatment jurisdictions (n ＝ 1,656, 6.7z), disease caused by atypical mycobacteria (n ＝ 257, 1.0z), negative results for both smear and culture (n ＝ 3,249, 13.1z), MDR TB treated with second-line agents (n ＝ 19, º0.1z), and unknown prior treatment history (n ＝ 266, 1.1z). Some TB patients met more than 1 exclusion criterion. Finally, 11,186 (45.0z) bacteriologically confirmed adult pulmonary TB patients were included in the analysis. Patients newly diagnosed with pulmonary TB received a standardized short-course chemotherapy consisting of 2 months of isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB), followed by 4 months of INH and RIF. Previously treated patients received 2 months of INH, RIF, PZA, and EMB and streptomycin (STR), 1 month of INH, RIF, PZA, and EMB, and 5 months of INH, RIF, and EMB (3) (4) (5) . Ethical approval for the study was obtained from the institutional review board of Istanbul University in accordance with the Helsinki recommendations (Approval# 2011/1543-718).
TB registry: There are 32 TB dispensaries in Istanbul; they collaborate with 1 of 2 main diagnostic laboratories subject to external quality control from the national TB reference laboratory in Ankara (3). In addition, the Provincial TB Control Director reviews data collection on a monthly basis. Data elements for the Turkish national TB program are based on the WHO Centralized Information System for Infectious Diseases data standards, EuroTB data file (2) . Clinical outcomes were evaluated 12 months after commencement of treatment.
Case characteristics: TB cases were classified according to bacteriological results, anatomical site, and treatment history (3) (4) (5) . New patients were defined as those who had never received treatment for TB or had taken anti-TB drugs for less than 1 month. Previously treated patients were defined as those who had received 1 month or more of anti-TB drugs. Cases are described with respect to the year of diagnosis, age at last birthday (categorized as 18-35, 36-50, 50-65, and À65 years), sex, and country of birth (Turkey/other). Treatment history was categorized as relapsed cases (i.e., a patient previously treated for TB who had been declared cured or who had completed the treatment and who is currently diagnosed according to positive smear or culture), interrupted treatment (i.e., a patient who returned for treatment and was positive after bacteriological tests following treatment interruption for 2 months or more), and treatment failure (i.e., a patient who started a retreatment regimen after failing previous treatment, defined as having a positive bacteriological result at month 5 of treatment).
Extrapulmonary involvement was categorized as present or absent on the basis of at least 1 bacteriologically or histologically positive extrapulmonary specimen or strong clinical evidence consistent with active extrapulmonary TB along with a clinical decision to treat with a full course of TB chemotherapy. Initial direct conventional microscopy was categorized as positive if (i) 2 or more initial sputum smear examinations were positive for acid-fast bacilli (AFB); (ii) 1 sputum smear examination was AFB-positive, and there were radiographic abnormalities consistent with active pulmonary TB as determined by a clinician; or (iii) 1 sputum smear was AFB-positive, and sputum culture in LoewensteinJensen medium or liquid culture method was positive for M. tuberculosis (3). The initial culture was categorized as positive if at least 1 sputum culture was positive.
Antibiotic resistance was based on standard testing of anti-TB medications and categorized as none, resistant to INH alone, resistant to INH and RIF with or without resistance to any other drug (i.e., MDR), and resistance to RIF with or without resistance to any other drug other than INH. Drug susceptibility tests were performed using proportion methodology (4). Treatment outcomes were defined as treatment success (i.e., cured or treatment completed), treatment default, death, or treatment failure (3, 4) . Default, death, and treatment failure outcomes were examined both individually and combined as any adverse outcome.
Data processing and statistical analysis: Data from the registry were provided in digital format and analyzed using SPSS 16.0 (IBM SPSS, Armonk, N.Y., USA). We randomly chose 20 cases from the computerized database to compare them against the original registry and found 100z concordance for all data elements. Continuous variables are expressed as means and standard deviations or medians and quartiles. We used multivariable logistic regression for the final analysis, and estimated the odds ratios (OR) and 95z confidence intervals (95z CI) to determine the association between risk factors and adverse outcomes after adjusting for age category and treatment history.
RESULTS

Patient characteristics:
The majority of patients were aged 18-35 years, over two-thirds were men, and over 98z were born in Turkey (Table 1) . Fewer than 15z received any previous TB treatment, and fewer than 4z had evidence of extrapulmonary involvement. Further, 87.0z of cases were found to be AFB positive on initial microscopy, and cultures were positive in 72.6z of cases. Drug resistance to any of the tested anti-TB antibiotics (i.e., INH, RIF, EMB, and STR) was observed in 10.9z of cases; the most common resistance pattern was to INH alone, accounting for 6.8z of cases.
Patient characteristics and treatment outcomes: Treatment success was accomplished in 91.0z of patients. There were 1,010 (9.0z) subjects with adverse treatment outcomes; more than two-thirds of these were due to treatment default. There was a significant positive trend toward an increased risk of adverse treatment outcomes with age; patients older than 65 years had nearly 3-fold higher odds of an adverse treatment outcome. Among the adverse outcomes, the increased risk associated with age À65 years was entirely restricted to death (OR, 45. Initial smear positivity for AFB was weakly associated with treatment failure (OR, 1.40; 95z CI, 1.06-1.84). Initial culture positivity conferred a modestly increased risk of treatment failure (OR, 2.50; 95z CI, 1.37-4.54). Among the 8,118 culture-positive TB patients, 3.2z of the isolates were MDR. TB patients with MDR had 10-fold greater odds of an adverse treatment outcome. This effect was more strongly associated with treatment failure (OR, 92.8; 95z CI, 56.1-153) and death (OR, 5.92; 95z CI, 3.13-11.2). Resistance to INH alone was not significantly associated with an increased risk of adverse treatment outcomes.
DISCUSSION
In this study, 1,010 (9.0z) patients undergoing TB treatment experienced an adverse outcome including treatment default (6.1z), death (1.8z), and treatment failure (1.1z). Patients older than 65 years had a markedly increased risk of death. Male patients had modestly increased odds of any adverse outcome, primarily due to increased default. Furthermore, patients born outside of Turkey had over 6-fold greater odds of a treatment default than those born in Turkey. Previous treatment history predicted the outcome of current therapy: patients with a history of interrupted treatment had over 10-fold increased odds of default, and patients with prior treatment failure had a 17-fold increased risk of current treatment failure. Antibiotic resistance had the strongest impact on outcome. Patients with MDR strains had over 90-fold increased odds of treatment failure and nearly 6-fold increased odds of death.
Treatment default was the most prevalent adverse outcome, occurring in 679 (6.1z) individuals with an adverse treatment outcome; the most important risk factor for treatment default was a history of prior default. The underlying mechanisms and risk factors for default may include biological factors (e.g., drug intolerance) and social factors (e.g., poor follow-up and lack of access to clinical services). Studies in other countries report that inadequate counseling, poor attitude of healthcare workers, alcohol use, changing residence, low educational level, feeling of shame over having TB, feeling better, and treatment outside the governmental program are associated with treatment default (14, 15) . (2, (16) (17) (18) and reduction of adverse treatment outcomes by 19 .2z between 1998 and 2000 in Istanbul (19) .
The effects of age and sex on treatment outcomes observed in the present study are consistent with findings in other populations. Age À 60 years was strongly associated with death (OR, 18.4; 95z CI, 12.12-27.92) in an analysis of TB treatment outcomes involving 15 European Union (EU) countries (20) . The increased risk of death with advancing age may be due to nonspecific age-related comorbidities or nonspecific biological changes affecting host immunological defenses. Male sex is associated with adverse treatment outcomes in national Turkish data as well as EU countries (2, (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . The increased risk in men is primarily due to treatment default, suggesting social factors are important rather than underlying biologic differences between the sexes. Patients born outside Turkey had a 5-fold greater odds of an adverse outcome. The increased risk of adverse treatment outcomes among immigrants has also been reported in other countries (28) . The increased risk in the present study was limited to treatment default, suggesting social factors are more important than underlying biologic differences.
Previous treatment history is strongly associated with adverse treatment outcomes. For example, patients with a history of interrupted treatment had increased odds of another treatment default. Similarly, patients with a history of treatment failure had markedly increased odds of treatment failure again. Thus, knowledge of treatment history provides important information about the risks associated with current treatment.
Antibiotic resistance most strongly influenced treatment outcomes. In particular, resistance to INH and RIF in combination (i.e., MDR) conferred more than 10-fold increased odds of an adverse outcome, predominantly treatment failure (OR, 92.8; 95z CI, 56.1-153) and death (OR, 5.92; 95z CI, 3.13-11.2). The prevalence of MDR strains (3.2z) in the present study was lower than the approximately 5z prevalence reported among all cases in Turkey between 2006 and 2009 (16-18) . However, resistance testing was not performed for 40z of isolates in the present study; therefore, it is possible that the true prevalence of MDR strains differs from the observed 3.2z. Nevertheless, it is unlikely that this potential bias contributes significantly to the observed increased risk of adverse treatment outcomes. International studies highlight the importance of antibiotic resistance in treatment outcomes. Espinal et al. reported similar increased risks of treatment failure and mortality among new TB cases with MDR in 6 countries in the Caribbean region, Asia, Europe, and South America (29) . Successful treatment of MDR TB is difficult yet critical for preventing the establishment and amplification of these strains (30, 31) .
One of the strengths of the present study is that it is situated in Istanbul, Turkey's largest city, which has the highest TB incidence in the country. The study included all eligible patients within the city catchment area, minimizing the effect of selection bias. The large number of patients allows adequate precision for examining subgroups of patients. The limitations of this study include the restriction of the analyses to bacteriologically confirmed adult pulmonary TB patients with data available for prior treatment history and treatment outcomes, limiting the generalizability of the present results to similar patients. In addition, TB patients not detected by the national health system were not included. Although this group is likely to be small, it is also likely to include marginalized groups such as the homeless, in whom antibiotic resistance, inadequate previous treatment, and challenging follow-up are likely to pertain; these factors may contribute to a greater prevalence of adverse outcomes than that reported here. Finally, 6.7z of candidate patients were transferred to other treatment jurisdictions; therefore, follow-up information was not available for them. It is possible that the outcomes of these patients differed from what we observed, and their inclusion could have altered the present results. However, this group is only a small portion of our sample, and any potential differences are unlikely to be large. TB treatment outcomes in Istanbul are favorable compared to international experience. The notable findings in this study include a treatment success rate of 91.0z and the identification of patient characteristics associated with adverse outcomes. These findings prompt several recommendations for improving care among TB patients. Patients with advanced age and prior treatment history, male patients, and those born outside of Turkey should be considered to have a higher risk of adverse outcomes, warranting increased vigilance and care. Prior treatment history is especially valuable in predicting problems likely to ensue with current therapy, especially treatment default and failure. The prevalence of antibiotic resistance serves as an indicator of community as well as individual health, highlighting the need for additional resources and attention. In particular, patients with MDR require substantial attention to avoid treatment failure and death as well as the establishment of MDR strains in the general population.
